Verna Porter, MD
Neurology · Santa Monica, CANPI 1730107012
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,706 of the $4,887 with a category attached, or 75.8%. 28 manufacturers reported payments, led by Biogen at 29.1% of the total. 2025 is the largest year on record at $1,719, 6.1 times the $281 reported in 2019.
Across 171 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- UCB, Inc.$825
- CSL Behring$476
- Acadia Pharmaceuticals Inc$433
- Lilly USA, LLC$274
- Argenx US, Inc.$264
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,18124%
- Food & beverage$3,70676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 10 | $1,424 |
| UCB, Inc. | 45 | $825 |
| CSL Behring | 19 | $476 |
| Acadia Pharmaceuticals Inc | 28 | $433 |
| Lilly USA, LLC | 12 | $274 |
| Argenx US, Inc. | 10 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $188 |
| Merz Pharmaceuticals, LLC | 4 | $130 |
| AstraZeneca(2 entities) | 4 | $119 |
| Lundbeck LLC | 4 | $114 |
| Neurocrine Biosciences, Inc. | 2 | $76 |
| Catalyst Pharmaceuticals, Inc. | 3 | $63 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Eisai Inc. | 2 | $47 |
| Harmony Biosciences LLC | 1 | $40 |
| GE HealthCare | 2 | $39 |
| Medtronic | 2 | $37 |
| Akcea Therapeutics, Inc. | 1 | $33 |
| AbbVie | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Novartis | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
How this compares
$4,887 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 208 | $31,789 |
| Rivastigmine | 32 | $12,151 |
| Donepezil Hcl | 501 | $7,325 |
| Memantine Hcl | 120 | $2,926 |
| Escitalopram Oxalate | 13 | $137 |
Paid to pharmacies, not to this prescriber.
Other neurology in Santa Monica
- David KudrowSanta Monica$532K
- Santosh KesariSanta Monica$397K
- Andrew WooSanta Monica$273K
- Danny BenmosheSanta Monica$268K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.